CombiMatrix Corp. CBMXW 深 滬

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion announced new data on icovamenib, an oral menin inhibitor, at ADA 2025. Preclinical studies show icovamenib enhances glycemic control and weight loss when combined with low-dose semaglutide, while preserving lean mass. It also rescues human myotube atrophy ex vivo. In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and a 55% increase in C-peptide at Week 26, demonstrating durable effects ...

06-23 11:00